DE602006016934D1 - Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen - Google Patents
Verfahren und zusammensetzungen zur behandlung von zns-erkrankungenInfo
- Publication number
- DE602006016934D1 DE602006016934D1 DE602006016934T DE602006016934T DE602006016934D1 DE 602006016934 D1 DE602006016934 D1 DE 602006016934D1 DE 602006016934 T DE602006016934 T DE 602006016934T DE 602006016934 T DE602006016934 T DE 602006016934T DE 602006016934 D1 DE602006016934 D1 DE 602006016934D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- cns diseases
- treating cns
- cns
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66929005P | 2005-04-06 | 2005-04-06 | |
US11/285,905 US7619007B2 (en) | 2004-11-23 | 2005-11-22 | Method and composition for administering an NMDA receptor antagonist to a subject |
PCT/US2006/013506 WO2006121560A2 (en) | 2005-04-06 | 2006-04-06 | Methods and compositions for treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006016934D1 true DE602006016934D1 (de) | 2010-10-28 |
Family
ID=37036831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006016934T Active DE602006016934D1 (de) | 2005-04-06 | 2006-04-06 | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen |
Country Status (18)
Country | Link |
---|---|
US (18) | US8058291B2 (de) |
EP (2) | EP2243475B1 (de) |
JP (1) | JP5666087B2 (de) |
KR (1) | KR101406456B1 (de) |
CN (1) | CN101247795B (de) |
AT (1) | ATE481096T1 (de) |
AU (1) | AU2006244297A1 (de) |
BR (1) | BRPI0607017B8 (de) |
CA (1) | CA2604052C (de) |
DE (1) | DE602006016934D1 (de) |
DK (1) | DK1874282T3 (de) |
HK (1) | HK1106711A1 (de) |
IL (1) | IL186504A0 (de) |
MX (1) | MX2007012374A (de) |
PL (1) | PL1874282T3 (de) |
RU (1) | RU2007140348A (de) |
WO (1) | WO2006121560A2 (de) |
ZA (1) | ZA200709535B (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
AU2003298514A1 (en) * | 2002-05-17 | 2004-05-04 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
CA2556214A1 (en) * | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP1845968A2 (de) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
JP5666087B2 (ja) | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
GB0519274D0 (en) * | 2005-09-21 | 2005-11-02 | Arakis Ltd | The treatment of neurodegenerative diseases |
CA2648495C (en) * | 2006-04-26 | 2016-07-05 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
WO2008005036A1 (en) * | 2006-07-05 | 2008-01-10 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of memantine |
GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
WO2009091932A2 (en) * | 2008-01-18 | 2009-07-23 | Adamas Pharmaceuticals, Inc. | Treatment of mild dementia of the alzheimer's disease type |
TWI491395B (zh) * | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
CN102883601A (zh) | 2009-12-02 | 2013-01-16 | 阿达玛斯医药公司 | 金刚烷胺组合物及其使用方法 |
EA037187B1 (ru) * | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
WO2011127235A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
US9662347B2 (en) * | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
EP2588104B1 (de) | 2010-07-01 | 2014-12-10 | Merck Sharp & Dohme Corp. | Positive allosterische isoindolon-m1-rezeptormodulatoren |
WO2012012656A2 (en) * | 2010-07-21 | 2012-01-26 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
RU2013121270A (ru) | 2010-10-12 | 2014-11-20 | Серекор Инк. | Композиции против кашля, содержащие мемантин |
DE102010053432A1 (de) * | 2010-12-06 | 2012-06-06 | Euroimmun Medizinische Labordiagnostika Ag | Verfahren zum Nachweis von anti-NMDA-Rezeptor Autoantikörpern zum Einsatz in Diagnoseverfahren |
AU2012214303A1 (en) * | 2011-02-09 | 2013-09-12 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
US20130323309A1 (en) * | 2011-02-17 | 2013-12-05 | Lupin Limited | Sustained Release Composition of Memantine |
CN103796645B (zh) * | 2011-08-31 | 2017-06-20 | 东洋油墨Sc控股株式会社 | 贴剂 |
PT2838517T (pt) * | 2012-04-18 | 2018-01-04 | Contera Pharma Aps | Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade |
JP2015523998A (ja) | 2012-06-19 | 2015-08-20 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 疾患を治療するための組成物および方法 |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014111790A2 (en) * | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
EP2961393B1 (de) * | 2013-02-28 | 2020-10-28 | Lupin Limited | Pharmazeutische zusammensetzungen von donepezil mit spezifischem in-vitro-auflösungsprofil oder pharmakokinetischen parametern |
CA2902665C (en) * | 2013-02-28 | 2021-03-02 | Lupin Limited | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
US11160785B2 (en) | 2013-03-15 | 2021-11-02 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP2968237A4 (de) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | Verfahren und zusammensetzungen zur verbesserung der kognitiven funktion |
CN105377371A (zh) | 2013-04-12 | 2016-03-02 | 西奈山伊坎医学院 | 创伤后应激障碍的治疗方法 |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
US20160220512A1 (en) * | 2013-09-15 | 2016-08-04 | Rubicon Research Private Limited | Modified release pharmaceutical formulations |
WO2015087927A1 (ja) * | 2013-12-12 | 2015-06-18 | 久光製薬株式会社 | カバー材付き貼付剤及びカバー材付き貼付剤キット |
CA2938671A1 (en) * | 2014-02-04 | 2015-08-13 | Forest Laboratories Holdings Limited | Donepezil compositions and method of treating alzheimer's disease |
TWI602585B (zh) | 2014-03-25 | 2017-10-21 | 林信湧 | 一種用於治療阿茲海默症之吸入式醫藥組成物及其備製方法 |
US10471040B2 (en) * | 2014-10-03 | 2019-11-12 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
CA2966195A1 (en) | 2014-11-04 | 2016-05-12 | Adamas Pharmaceuticals, Inc. | Oral adamantine in the treatment of gait disorders in multiple sclerosis patients |
ITUB20150635A1 (it) * | 2015-04-14 | 2016-10-14 | Giuseppe Lotito | Uso di un inibitore dell’aceticolinesterasi e composizioni farmaceutiche contenenti detto inibitore. |
US20160324852A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
AU2016268096B2 (en) | 2015-05-22 | 2021-04-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
CN108350071A (zh) * | 2015-08-17 | 2018-07-31 | 德国神经退行性疾病中心 | 结合到抗N-甲基-D-天冬氨酸(NMDA)受体抗体的结合区的抗体或抗体片段或非Ig支架 |
KR101882224B1 (ko) * | 2015-09-02 | 2018-07-26 | 한국프라임제약주식회사 | 콜린 알포세레이트 및 메만틴을 함유하는 복합 조성물 |
CN105326837A (zh) * | 2015-10-09 | 2016-02-17 | 北京万全德众医药生物技术有限公司 | 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊 |
MA43532A (fr) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals Inc | Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques |
CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
KR102508993B1 (ko) | 2016-07-27 | 2023-03-10 | 코리움, 인크. | 메만틴 경피 송달 시스템 |
CN109789134A (zh) | 2016-07-27 | 2019-05-21 | 考里安国际公司 | 与口服递送药代动力学生物等效的透皮递送系统 |
KR20230097203A (ko) | 2016-07-27 | 2023-06-30 | 코리움, 엘엘씨 | 도네페질 경피 전달 시스템 |
WO2018062941A1 (ko) * | 2016-09-30 | 2018-04-05 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
US20190343780A1 (en) * | 2016-12-22 | 2019-11-14 | Rvx Therapeutics Ltd. | Low dose drug combinations for use in preventing and treating neuronal damage |
CN115715769A (zh) * | 2017-05-19 | 2023-02-28 | 比斯坎神经治疗公司 | 石杉碱的改良释放药物组合物以及其使用方法 |
AU2018320946A1 (en) | 2017-08-24 | 2020-04-16 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
CA3081604A1 (en) * | 2017-11-22 | 2019-05-31 | Panorama Research, Inc. | Aminoadamantyl nitrate compounds and their use to treat cns disorders |
US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
KR102224917B1 (ko) * | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
WO2020208398A1 (es) | 2019-04-09 | 2020-10-15 | Laboratorios Bagó S.A. | Composición farmacéutica en polvo con memantina y donepecilo para utilizar en el tratamiento de la enfermedad de alzheimer |
US11602507B2 (en) | 2019-05-27 | 2023-03-14 | Trikona Pharmaceuticals Pvt. Ltd | Extended release oral composition of memantine or its salt and its process for the preparation |
WO2020240505A1 (en) | 2019-05-31 | 2020-12-03 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Immediate release fixed-dose combination of memantine and donepezil |
KR20220047970A (ko) * | 2019-06-28 | 2022-04-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 알츠하이머병의 치료를 위한 비강내 단트롤렌 투여 |
WO2021234475A1 (en) * | 2020-05-21 | 2021-11-25 | Pellets Pharma Limited | Modified release compositions and methods of memantine hcl extended release, donepezil hcl immediate release pellets |
CU20200087A7 (es) | 2020-11-24 | 2022-07-08 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
WO2023077122A1 (en) * | 2021-11-01 | 2023-05-04 | Nitrase Therapeutics, Inc. | Methods of diagnosing a synucleinopathy |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152180A (en) | 1960-08-25 | 1964-10-06 | Studiengesellschaft Kohle Mbh | Process for the production of nu-tert-alkyl amides and, if desired, nu-tert. alkyl amines |
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
GB1175820A (en) | 1966-02-18 | 1969-12-23 | Upjohn Co | Amino-Adamantane Derivatives |
FR2219159A1 (en) | 1973-02-23 | 1974-09-20 | Commissariat Energie Atomique | Adamantane nitroxide radicals - antiviral and anticancer agents, also useful in nuclear resonance magnetometry |
US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
US4148896A (en) | 1978-02-22 | 1979-04-10 | E. I. Du Pont De Nemours And Company | Antidepressant combination |
DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3280308D1 (de) | 1981-04-24 | 1991-04-04 | Squibb & Sons Inc | Verwendung von nadolol zur herstellung peroraler formen fuer die behandlung von glaukom. |
US4346112A (en) | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
JPS584718A (ja) | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
DK150008C (da) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
AU576889B2 (en) | 1984-07-24 | 1988-09-08 | Key Pharmaceuticals, Inc. | Adhesive transdermal dosage layer |
US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
ES2029805T3 (es) | 1986-04-16 | 1992-10-01 | Asta Pharma Aktiengesellschaft | Procedimiento para preparar un producto que contiene amantadina y selegilina en asociacion sinergica. |
FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
US4878913A (en) * | 1987-09-04 | 1989-11-07 | Pfizer Hospital Products Group, Inc. | Devices for neural signal transmission |
US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
JP3158435B2 (ja) | 1989-10-26 | 2001-04-23 | 日本新薬株式会社 | 徐放性製剤 |
ATE139574T1 (de) | 1989-11-06 | 1996-07-15 | Cell Genesys Inc | Herstellung von proteinen mittels homologer rekombination |
IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
CA2037178A1 (en) | 1990-02-28 | 1991-08-29 | Albert Walter Brzeczko | Deprenyl/l-dopa/carbidopa pharmaceutical composition |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
IN172468B (de) | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US6764697B1 (en) | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
KR100221695B1 (ko) | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
DE4236752A1 (de) | 1992-10-30 | 1994-05-05 | Asta Medica Ag | Kombinationspräparat aus Flupirtin und Morphin zur Behandlung von Schmerzen und zur Vermeidung der Morphin-Abhängigkeit |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
CA2115792C (en) | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
US5648087A (en) | 1993-03-09 | 1997-07-15 | Sanofi Sante Nutrition Animale | Anaesthetic pharmaceutical composition comprising a general anaesthetic and selegiline |
AU676315B2 (en) | 1993-06-30 | 1997-03-06 | Takeda Chemical Industries Ltd. | Stabilized solid pharmaceutical preparation and method of producing the same |
WO1995003052A1 (en) * | 1993-07-22 | 1995-02-02 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
US6908910B2 (en) | 1993-08-06 | 2005-06-21 | The Children's Medical Center Corporation | Estrogenic compounds as anti-mitotic agents |
CA2176712C (en) | 1993-11-16 | 2000-05-23 | Mantripragada Sankaram | Synthetic membrane vesicles with controlled release of encapsulated biologically active substances |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
US5484608A (en) | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
DE19510189A1 (de) | 1995-03-21 | 1996-09-26 | Hartmut Dr Goebel | Verwendung von Amantadin |
US5677349A (en) | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
ATE258067T1 (de) | 1995-05-26 | 2004-02-15 | Pfizer | Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält |
DE19528388A1 (de) | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US6095148A (en) * | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
ATE293458T1 (de) | 1996-08-23 | 2005-05-15 | Algos Pharm Corp | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
US5958919A (en) | 1996-09-20 | 1999-09-28 | Washington University | Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration |
US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
US6110498A (en) | 1996-10-25 | 2000-08-29 | Shire Laboratories, Inc. | Osmotic drug delivery system |
DE19644998C1 (de) | 1996-10-30 | 1998-06-10 | Hanns Prof Dr Ludwig | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
JPH10203966A (ja) | 1996-11-21 | 1998-08-04 | Takeda Chem Ind Ltd | 徐放性マイクロカプセルおよびその製造法 |
DE69738966D1 (de) | 1996-12-20 | 2008-10-16 | Mcneil Ppc Inc | Durch ionenaustauscherharze verabreichte hustenmittel |
KR20000010907A (ko) | 1997-03-11 | 2000-02-25 | 야스따까 이시이 | 아다만탄 유도체 및 그의 제조 방법 |
DE69805909T2 (de) | 1997-04-10 | 2002-09-26 | Pfizer | Fluorosubstituierte Adamantan-Derivate |
EP0980247A1 (de) | 1997-05-07 | 2000-02-23 | Algos Pharmaceutical Corporation | Zusammensetzung und behandlung aus kombinationen von antidepressivamit einem nmda rezeptor antagonist, für neuropatische schmerzen |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MA26553A1 (fr) | 1997-10-17 | 2004-12-20 | Centaur Pharmaceuticals Inc | Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la |
US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
DE19834764A1 (de) * | 1998-08-01 | 2000-02-03 | Univ Hannover | Mittel zur Stabilisierung von Lebensmitteln und kosmetischen Mitteln sowie Verfahren zu dessen Herstellung |
CZ302630B6 (cs) | 1998-08-27 | 2011-08-10 | Pharmacia & Upjohn Ab | Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu |
ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
US8545880B2 (en) | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
JP4543553B2 (ja) | 1999-03-03 | 2010-09-15 | オプティノーズ アズ | 鼻用の送り込み装置 |
SE9901077D0 (sv) | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
JP2003509439A (ja) | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
NZ529928A (en) | 1999-10-29 | 2005-10-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
CA2389865A1 (en) * | 1999-11-04 | 2001-05-10 | Xel Herbaceuticals | Transdermal administration of huperzine |
US20020071863A1 (en) | 1999-12-09 | 2002-06-13 | Dong Liang C. | Antiviral medication |
MXPA02006216A (es) | 1999-12-22 | 2004-02-26 | Nektar Therapeutics Al Corp | Derivados estericamente impedidos de polimeros solubles en agua. |
US6491949B2 (en) | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US6455066B1 (en) | 2000-03-10 | 2002-09-24 | Epicept Corporation | Intradermal-penetration agents for topical local anesthetic administration |
EP1559418A1 (de) | 2000-06-26 | 2005-08-03 | EpiCept Corporation | Zusammensetzungen zur Schmerzbehandlung der Schleimhaut |
US6648083B2 (en) | 2000-11-02 | 2003-11-18 | Schlumberger Technology Corporation | Method and apparatus for measuring mud and formation properties downhole |
US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
EP1389181A4 (de) | 2001-04-02 | 2005-10-19 | Panorama Res Inc | Nitroxid- und nitron-antioxidationsmittel als therapeutika |
DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
US6500454B1 (en) | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
WO2003077897A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
IL149055A0 (en) | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
TW531966B (en) * | 2002-05-20 | 2003-05-11 | Mediatek Inc | Phase lock loop with low static state phase error and calibration circuit |
US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
US6662845B1 (en) | 2002-06-19 | 2003-12-16 | Newell Operating Company | Roman shade with separated backing sheet |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
AU2003256308B2 (en) | 2002-06-26 | 2008-07-03 | Intarcia Therapeutics, Inc. | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
WO2004012741A1 (en) * | 2002-07-29 | 2004-02-12 | Glaxo Group Limited | Sustained release formulations comprising lamotrigine |
US20050208132A1 (en) | 2002-07-29 | 2005-09-22 | Gayatri Sathyan | Methods and dosage forms for reducing side effects of benzisozazole derivatives |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US6913768B2 (en) | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20050075679A1 (en) * | 2002-09-30 | 2005-04-07 | Gliner Bradford E. | Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system |
CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
AU2003283688A1 (en) * | 2002-12-11 | 2004-06-30 | Pfizer Products Inc. | Controlled-release of an active substance into a high fat environment |
CA2510465A1 (en) | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
EP1595535A2 (de) | 2002-12-23 | 2005-11-16 | Osmotica Costa Rica Sociedad Anonima | Venlafaxin- und memantinhaltige abgabevorrichtung sowie anwendungsverfahren dafür |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
US20050065219A1 (en) | 2003-03-27 | 2005-03-24 | Lipton Stuart A. | Treatment of demyelinating conditions |
CA2525195A1 (en) * | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders |
US20050124701A1 (en) | 2003-06-11 | 2005-06-09 | Went Gregory T. | Method of targeting a therapeutic agent |
KR20060033727A (ko) | 2003-06-16 | 2006-04-19 | 알러간, 인코포레이티드 | 메만틴 경구 투여 제형 |
US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
KR100524018B1 (ko) | 2003-07-25 | 2005-10-26 | 삼성전자주식회사 | 이동형 디스플레이장치 및 이동형 디스플레이 시스템 |
US20050037364A1 (en) * | 2003-08-13 | 2005-02-17 | International Business Machines Corporation | Techniques for recording signals |
ATE411015T1 (de) | 2003-10-22 | 2008-10-15 | Merz Pharma Gmbh & Co Kgaa | Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien |
EP1684806B1 (de) | 2003-11-21 | 2008-06-25 | Memory Pharmaceuticals Corporation | Zusammensetzungen enhaltend l-typ-calciumcanalblockern und cholinesterase-hemmern |
US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7553858B2 (en) | 2003-12-17 | 2009-06-30 | Meda Pharma Gmbh & Co. Kg | Combination of flupirtine and tramadol |
CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
EP1703902B1 (de) | 2004-01-05 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Memantin für die behandlung von leichtem bis mittelschwerem morbus alzheimer |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
WO2005079756A2 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
CA2556214A1 (en) | 2004-02-13 | 2005-09-01 | Neuromolecular, Inc. | Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
EP1742624B1 (de) | 2004-02-18 | 2010-01-06 | Sepracor, Inc. | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
EP1740172A4 (de) | 2004-03-19 | 2007-10-10 | Axonyx Inc | Acetylcholinesterase-hemmer und n-methyl-d-aspartat-antagonisten zur behandlung von kognitiven störungen |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
AU2005265031A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US7346382B2 (en) * | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
US20060052370A1 (en) | 2004-08-24 | 2006-03-09 | Meyerson Laurence R | Methods and compositions for treating nociceptive pain |
US20060240043A1 (en) | 2004-10-08 | 2006-10-26 | Meyerson Laurence R | Methods and compositions for treating migraine pain |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP1845968A2 (de) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Zusammensetzung mit einem nmda-rezeptor-antagonisten und levodopa und ihre verwendung zur behandlung von neurologischen erkrankungen |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
US8252331B2 (en) | 2004-12-03 | 2012-08-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Osmotic device containing amantadine and an osmotic salt |
US20060160852A1 (en) | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
WO2006089066A1 (en) | 2005-02-15 | 2006-08-24 | Neuromolecular Pharmaceuticals, Inc. | Combinations therapy for treatment of demyelinating conditions |
JP5666087B2 (ja) | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
AU2006259619A1 (en) | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
ES2521494T3 (es) | 2007-04-02 | 2014-11-12 | Parkinson's Institute | Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos |
-
2006
- 2006-04-06 JP JP2008505658A patent/JP5666087B2/ja active Active
- 2006-04-06 DE DE602006016934T patent/DE602006016934D1/de active Active
- 2006-04-06 AT AT06749777T patent/ATE481096T1/de not_active IP Right Cessation
- 2006-04-06 BR BRPI0607017A patent/BRPI0607017B8/pt active IP Right Grant
- 2006-04-06 US US11/399,879 patent/US8058291B2/en active Active
- 2006-04-06 DK DK06749777.6T patent/DK1874282T3/da active
- 2006-04-06 AU AU2006244297A patent/AU2006244297A1/en not_active Abandoned
- 2006-04-06 EP EP10075323.5A patent/EP2243475B1/de active Active
- 2006-04-06 MX MX2007012374A patent/MX2007012374A/es active IP Right Grant
- 2006-04-06 PL PL06749777T patent/PL1874282T3/pl unknown
- 2006-04-06 RU RU2007140348/15A patent/RU2007140348A/ru not_active Application Discontinuation
- 2006-04-06 KR KR1020077025686A patent/KR101406456B1/ko active IP Right Grant
- 2006-04-06 WO PCT/US2006/013506 patent/WO2006121560A2/en active Application Filing
- 2006-04-06 EP EP06749777A patent/EP1874282B1/de not_active Revoked
- 2006-04-06 CA CA2604052A patent/CA2604052C/en active Active
- 2006-04-06 CN CN2006800166301A patent/CN101247795B/zh active Active
-
2007
- 2007-10-08 IL IL186504A patent/IL186504A0/en unknown
- 2007-11-06 ZA ZA200709535A patent/ZA200709535B/xx unknown
-
2008
- 2008-01-10 HK HK08100318.7A patent/HK1106711A1/xx not_active IP Right Cessation
-
2010
- 2010-04-02 US US12/753,769 patent/US8293794B2/en active Active
- 2010-04-09 US US12/757,795 patent/US8283379B2/en active Active
-
2012
- 2012-06-28 US US13/536,763 patent/US8338486B2/en active Active
- 2012-06-28 US US13/536,588 patent/US8338485B2/en active Active
- 2012-07-26 US US13/559,478 patent/US20120288560A1/en not_active Abandoned
- 2012-12-21 US US13/725,246 patent/US8580858B2/en active Active
-
2013
- 2013-04-15 US US13/863,140 patent/US20140134243A1/en not_active Abandoned
-
2015
- 2015-02-03 US US14/613,220 patent/US20150297537A1/en not_active Abandoned
-
2016
- 2016-04-04 US US15/090,400 patent/US20160250149A1/en not_active Abandoned
- 2016-04-04 US US15/090,416 patent/US20160220545A1/en not_active Abandoned
- 2016-04-04 US US15/090,429 patent/US20160243093A1/en not_active Abandoned
- 2016-04-04 US US15/090,396 patent/US20160243035A1/en not_active Abandoned
- 2016-04-29 US US15/142,519 patent/US20160243058A1/en not_active Abandoned
- 2016-04-29 US US15/142,133 patent/US20160243094A1/en not_active Abandoned
- 2016-04-29 US US15/142,253 patent/US20160243095A1/en not_active Abandoned
- 2016-04-29 US US15/142,492 patent/US20160250161A1/en not_active Abandoned
-
2017
- 2017-10-23 US US15/790,710 patent/US20180263914A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006016934D1 (de) | Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen | |
DE602005020580D1 (de) | Stereoisomere verbindungen und verfahren zur behandlung von erkrankungen des magen-darm-trakts und des zentralen nervensystems | |
ATE493433T1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
DE60124080D1 (de) | Verbindungen und verfahren zur behandlung der alzheimerschen krankheit | |
DE602006018583D1 (de) | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten | |
ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
ATE522229T1 (de) | Anti-ngf-antikörper zur behandlung verschiedener erkrankungen | |
DE69942702D1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
ATE331527T1 (de) | Verfahren zur behandlung von brustdrüsenerkrankungen | |
ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
DE602004019897D1 (de) | Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen | |
EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
ATE445644T1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
ATE473277T1 (de) | Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten | |
ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
DE602004021358D1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
DE602004023100D1 (de) | Verbindungen und verfahren zur behandlung von dyslipidemie | |
DE602005027228D1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
DE602004023102D1 (de) | Verfahren zur herstellung kristalliner formen von orlistat | |
TW200510351A (en) | Oxazole compounds for the treatment of neurodegenerative disorders |